Add the power of partnering to your next conference with partneringONE® or groupsPLUS™. Find out more on our new pages here.


Over USD 20 billion in partnering transactions have been concluded each year for the past four years in biotech with sometimes dramatic results for both major pharmaceutical companies and smaller biotechs. EBD Group believes the coming years will see dealmaking rise significantly from the current plateau to achieve extraordinary new levels.

The Next-Big-Thing . . . Is Not A Drug, predicts BioWorld, the daily journal tracking trends in the biotechnology and pharmaceutical markets. While drugs continue to dominate conversation, a transaction trend is driving a converging industry that is "abuzz with news of deals," says BioWorld.